Skip to main content

A rapid, non-invasive, cost-effective, analytical device for bacterial or viral infection diagnosis through ultra-high sensitivity breath analysis.

Obiettivo

The world faces a growing epidemic of antimicrobial resistance (AMR); however, only two new classes of antibiotics have been brought to the market in the last 30 years. The discovery and development of new antibiotics is essential to maintain medical advances but poses significant scientific, clinical, and financial challenges, particularly for antibiotics active against Gram-negative bacteria (such as E. coli). Such bacteria have effective barriers against drugs, making treatment difficult, resistance likely and development costs and risks high. In addition, any new antibiotics brought to the market would likely be used cautiously to delay the development of resistance, adding an additional financial challenge in recouping the development costs. The O’Neill Report on AMR identifies diagnostics as critical to the battle against antibiotic resistance.

This innovation action, BreathSpec, proposes a viable solution to the global problem of AMR through the final developmental stages of an existing diagnostic device, which will allow a rapid, binary decision to be made on the need for antibiotic treatment, and which with suitable optimisation will allow further differentiation and stratification to take place. The Innovation Action includes technical developments to optimise its function, data acquisition for the development of the decision making analytical function and clinical validation.

It addresses these issues by producing reliable identification and quantification of key signature volatiles present in exhaled breath. It provides a non-invasive method for monitoring the volatile organic compounds present in an individual’s exhaled breath (and subsequently the blood) and has long been recognised as having significant utility as a clinical test that can be used for early disease detection and monitoring, and potentially to diagnose specific bacterial infections for better, more targeted use of existing antibiotics.

Invito a presentare proposte

H2020-FTIPilot-2016-1
Vedi altri progetti per questo bando

Meccanismo di finanziamento

IA - Innovation action

Coordinatore

IMSPEX DIAGNOSTICS LIMITED
Indirizzo
Ty Menter, Navigation Park, Rct
CF45 4SN Abercynon
United Kingdom
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contributo UE
€ 1 141 700

Partecipanti (4)

G.A.S. GESELLSCHAFT FUR ANALYTISCHESENSORSYSTEME M.B.H.
Germania
Contributo UE
€ 507 150
Indirizzo
Otto Hahn Strasse 15
44227 Dortmund
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
STATISTICAMEDICA LIMITED
Irlanda
Contributo UE
€ 462 087,50
Indirizzo
26 Belarmine Court Enniskerry Road Stepaside
D18 Dublin
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
REDKNIGHT CONSULTANCY LTD
United Kingdom
Contributo UE
€ 116 287,50
Indirizzo
21 The Dairy
CF728TT Pontyclun
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
THE UNIVERSITY OF WARWICK
United Kingdom
Contributo UE
€ 140 422,50
Indirizzo
Kirby Corner Road - University House
CV4 8UW Coventry
Tipo di attività
Higher or Secondary Education Establishments